Dosages & Reactions

Interactions:

Acenocoumarol
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Nimodipine and Acenocoumarol should be monitored for excessive bleeding, especially from the gastrointestinal tract.
Amiodarone
Adverse Effect: Atrioventricular block and slowing of sinus rate
Clinical Management: Concurrent use of amiodarone and Nimodipine should be avoided in patients with sick sinus syndrome or partial AV (atrioventricular) block.
Atenolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Bisoprolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Carbamazepine
Adverse Effect: Decreased nimodipine effectiveness
Clinical Management: Monitor clinical response to nimodipine, with dose adjustments as needed to achieve or maintain cardiovascular response.
Celecoxib
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Celecoxib and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Celiprolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Flurbiprofen
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Flurbiprofen and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ibuprofen
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Ibuprofen and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Indomethacin
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Indomethacin and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ketoprofen
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Ketoprofen and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ketorolac
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Ketorolac and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Mefenamic Acid
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Mefenamic Acid and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Meloxicam
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Metoprolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Nabumetone
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Nabumetone and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Naproxen
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Naproxen and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Nimesulide
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Nimesulide and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Oxprenolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Oxyphenbutazone
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Oxyphenbutazone and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Paracetamol
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Paracetamol and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Phenacetin
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Phenacetin and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Phenindione
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Nimodipine and Phenindione should be monitored for excessive bleeding, especially from the gastrointestinal tract.
Phenobarbitone
Adverse Effect: Decreased nimodipine effectiveness
Clinical Management: Monitor patient for clinical signs or symptoms of continuing neurologic deficit which might be due to inadequate or diminished Nimodipine effect. Dose increases may be required.
Phenylbutazone
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Phenylbutazone and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Phenytoin
Adverse Effect: Decreased nimodipine effectiveness
Clinical Management: Monitor for continuing clinical effectiveness of nimodipine. Larger than expected doses may be required.
Pindolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Piroxicam
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Primidone
Adverse Effect: Decreased nimodipine effectiveness
Clinical Management: Monitor patient for clinical signs or symptoms of continuing neurologic deficit which might be due to inadequate or diminished Nimodipine effect. Dose increases may be required.
Propranolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Rifampicin
Adverse Effect: Decreased nimodipine efficacy
Sodium Valproate
Adverse Effect: Nimodipine toxicity (dizziness, headache, flushing, peripheral edema)
Clinical Management: Monitor for clinical or toxic effects of nimodipine (hypotension is most likely). Downward dose adjustment may be necessary to maintain desired cardiovascular response.
Tenoxicam
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Tenoxicam and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Warfarin
Adverse Effect: Increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Nimodipine and Warfarin should be monitored for excessive bleeding, especially from the gastrointestinal tract.

Naloxone Hydrochloride

Naproxen

Neomycin Sulfate

Neostigmine Bromide

Niacin(nicotinic acid)

Nifedipine

Nitrofurantoin

Nitroprusside Sodium

Norepinephrine Bitartrate

Nortriptyline Hydrochloride

Nystatin

Nitrofurazone